CD34 and Bcl-2 as predictors for the efficacy of neoadjuvant chemotherapy in cervical cancer

Lin, Yun; Li, Zhi; Liu, Mubiao; Yé, Haiyan; He, Jiaxun; Chen, Jianguo

doi:10.1007/s00404-020-05921-8

Cited by 6 publications

(3 citation statements)

References 37 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its coded products can bind to the corresponding kinases, thus promoting the development of cell cycle and enhancing cell vitality 19 . Bcl-2 is an apoptosis-inhibiting gene, which plays a role by antagonizing the apoptosis-promoting gene Bax 20 . Caspase-3 is a pro-apoptosis gene, which is activated by the mitochondrial and death receptor pathways, and then causes cell apoptosis 21 .…”

Section: Discussionmentioning

confidence: 99%

Expression of MiR-20a-5p and its target gene in colon cancer and its effect on the proliferation and apoptosis of colon cancer cells.

Tang

Lin

Wang

et al. 2023

Investigación Clínica

View full text Add to dashboard Cite

Abstract. We investigated the expression of micro ribonucleic acid (miR)-20a-5p and its target gene, breast cancer metastasis suppressor 1 like (BRMS1L), in colon cancer tissues and their effects on the proliferation and apoptosis of colon cancer cells. The dual luciferase assay was used to detect the targeted regulation of miR-20a-5p on BRMS1L. The expression levels of miR-20a-5p and BRMS1L in colon cancer tissues and cells were detected by quantitative real-time polymerase chain reaction (qRT-PCR). MiR-20a-5p mimic and mimic negative control (NC) were transfected into the colon cancer cell line SW480 by the liposome transient transfection method. The MTT assay, monoclonal formation of cancer cells, and flow cytometry were used to detect cell proliferation and apoptosis. The expres-sion level of miR-20a-5p in colon cancer tissues was significantly higher than that in adjacent tissues, and the expression level of BRMS1L was significantly lower than that in adjacent tissues. The expression level of miR-20a-5p was significantly correlated with tumor-node-metastasis (TNM) stage, lymph node metastasis, in-vasion depth, and differentiation degree. The higher the expression level of miR-20a-5p, the more advanced the TNM stage and invasion depth, and the easier it is for lymph nodes to metastasize (p<0.05). Compared with the control and the miR-NC groups, the miR-20a-5p group’s cell proliferation ability, expression of CyclinD1 and B-cell lymphoma-2 (Bcl-2) were significantly increased, while apoptosis ability and caspase-3 protein expression were significantly decreased (p<0.05). The expression of miR-20a-5p in colon cancer tissues and cells in-creased. Overexpression of miR-20a-5p could promote the proliferation of colon cancer cells and inhibit their apoptosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Expression of MiR-20a-5p and its target gene in colon cancer and its effect on the proliferation and apoptosis of colon cancer cells.

Tang

Lin

Wang

et al. 2023

Investigación Clínica

View full text Add to dashboard Cite

show abstract

“…Authors consider that high expression of CD34 signifies the presence of an anomalous vessel pattern and disturbing tumor vasculature is one of the primary strategies in cancer chemotherapy. Moreover, this marker has an important diagnostic and prognostic value -the decrease of CD34 expression after therapy correlates with its effectiveness [21].…”

Section: Discussionmentioning

confidence: 99%

The influence of diabetes mellitus on blood vessels amount in case of breast cancer

Foca,

Brinza,

Portnoi

et al. 2023

MJHS

View full text Add to dashboard Cite

Introduction. Breast cancer is one of the most common cancers in females worldwide. There are evidences that women with diabetes mellitus have a 40% higher risk of mortality. CD34 is a cell surface glycoprotein, which functions as a cellcell adhesion factor. Although its expression is traditionally related to hematopoietic cells, it is actually found on many other types of cells, endothelial too. Nowadays there are evidences that CD34 is a prognostic indicator by emphasizing its low expression in malignant tumors compared to benign ones. The aim of study was to determine the presence and numerical distribution of CD34+ vessels in the normal mammary gland, as well as in NST breast carcinomas, with and without diabetes mellitus type 2. Materials and methods. We processed immunohistochemically 58 invasive breast carcinomas of NST type. In 29 of cases, tumors were associated with diabetes. Results. The present study did not reveal any statistical and morphological differences in CD34 expression between compared groups. Conclusions. The expression of CD34 in breast cancer stroma is not homogenous, irrespective of association with diabetes mellitus type 2. The question if breast carcinoma and diabetes mellitus are concurrent or associated disorders remains open. Probably, the effect of carcinoma prevails in influencing the structure of the tumor microenvironment. We expect a further confirmation in larger study groups.

show abstract

“…Microsatellite instability -high (MSI-H), programmed cell death ligand 1 (PD-L1) expression, and high tumor mutational burden (TMB) are the most actively investigated biomarkers (8). Other factors with antitumor activity (e.g., microRNAs, B-cell lymphoma-2 (Bcl-2), and C-kit) were also investigated in preclinical studies; however, those factors were not found to be good predictors of the effect of immunotherapy at this time (9)(10)(11)(12).…”

Section: Introductionmentioning

confidence: 99%

Case Report: Partial response to single-agent pembrolizumab in a chemotherapy-resistant metastatic pancreatic cancer patient with a high tumor mutation burden

Dai

Sheng²,

Zhang³

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Single-agent immune checkpoint blockade has shown no clinical benefits in pancreatic cancer. Recently, the programmed cell death protein 1 (PD-1) antibody pembrolizumab has been recommended as a treatment option for high tumor mutational burden (TMB) solid tumors based on the data from a basket trial. However, no pancreatic cancer patients were enrolled in that trial. Whether pancreatic cancer patients with high TMB respond to PD-1 blockade as well remains unclear. Here, we report a case with a partial response to single-agent immunotherapy with pembrolizumab in pancreatic cancer with high TMB after the failure of several lines of chemotherapy. This result indicates that single-agent immunotherapy may be effective in pancreatic cancer patients with high TMB. In addition, in order to understand the basic immune state of our patients, we also analyzed the changes in immune cells in peripheral blood with cytometry by time-of-flight mass spectrometry (CyTOF) before and after pembrolizumab treatment.

show abstract

CD34 and Bcl-2 as predictors for the efficacy of neoadjuvant chemotherapy in cervical cancer

Cited by 6 publications

References 37 publications

Expression of MiR-20a-5p and its target gene in colon cancer and its effect on the proliferation and apoptosis of colon cancer cells.

Expression of MiR-20a-5p and its target gene in colon cancer and its effect on the proliferation and apoptosis of colon cancer cells.

The influence of diabetes mellitus on blood vessels amount in case of breast cancer

Case Report: Partial response to single-agent pembrolizumab in a chemotherapy-resistant metastatic pancreatic cancer patient with a high tumor mutation burden

Contact Info

Product

Resources

About